News

The FDA granted DT120 (lysergide) ODT Breakthrough Therapy designation for MDD, citing promising phase 3 Emerge data.

The FDA granted lonvo-z priority review for HAE, setting a PDUFA date of March 10, 2027 based on positive Phase 3 HAELO data.

Abbott's dual-energy PFA/RF ablation catheter met its primary effectiveness and safety endpoints in the 12-month FlexPulse IDE study behind its FDA nod.

Ross Levy, MD, on how Skin Angels invests in dermatology innovation and where he sees the field heading over the next 5 - 10 years.

Semaglutide was linked to fewer asthma attacks and COPD flare-ups than sulfonylureas, with no effect seen for other GLP-1 therapies.

Sciurba, of University of Pittsburgh, discusses full phase 3 OBERON and TITANIA results, including stronger responses in current smokers.

The oral STAT6 degrader achieved deep STAT6 suppression, up to 63% EASI reduction, and gains in asthma and rhinitis scores by week 4.

Hurst discusses data showing durably raised protective AAT levels in patients with alpha-1 antitrypsin deficiency.

Rahul Aggarwal, MD, MBA, shares the results of his retrospective cohort study investigating the residual risk of heart failure after patients with prior MI.

Pooled data from 3 trials show H-ISDN cuts all-cause and cardiovascular death in HFrEF, though heterogeneity limits clinical impact.

Dell discusses an analysis of VOYAGE showing dupilumab more than doubled the odds of favorable asthma outcomes in children, regardless of baseline ICS dose.

Castro, of University of Kansas discusses interim phase 1b data showing rapid, durable suppression in patients with mild to moderate asthma.

At ERS 2026, John Oppenheimer, MD, discusses how PERFORM supports earlier escalation in patients with uncontrolled, infrequently exacerbating asthma.

ADVANCE Outcomes at ERS 2026 demonstrated improved odds of improvement and reduced odds of worsening.

Charalambos Antoniades, MD, PhD, discusses the recent trial investigating an AI-powered stroke and atrial fibrillation predictor.

The oral RARβ/γ agonist improved FVC and reduced fibrotic biomarkers over 12 weeks in a phase 2a trial presented at the ERS Congress 2026.

A COPD genetic risk score was linked to reduced lung function growth from birth to age 6, but only in children with high air pollution exposure.

Kyle Hogarth, MD, urges physicians to complete Alpha-1 testing during every COPD or asthma workup, warning that skipped tests delay diagnosis.

Deepak Bhatt, MD, MPH, MBA, discusses the next steps for pacibekitug in cardiovascular disease following its success in the phase 2 trial.

Novartis announced pelacarsen did not meet its primary endpoint in the phase 3 Lp(a)HORIZON cardiovascular outcomes trial despite Lp(a) lowering.

Paired airway and tissue sampling from 100 patients found greater microplastic burden in those with lung cancer.

Ross Levy, MD, explains why the LEADderm Skin Angels panel matters and what dermatology innovation looks like in daily practice.

Nurse practitioners discuss escalating biologic therapy for asthma and COPD, mucus plugging data, and access barriers.

A post hoc ALPACA analysis presented at ESC Congress 2026 shows lepodisiran cut Lp(a)-bound oxidized phospholipids by up to 94% at the 400-mg dose.

A roundup of dermatology's biggest August headlines, from an FDA approval to conference previews and conversations on equity in care.

Deepak Bhatt, MD, MPH, MBA, discusses the efficacy of this investigational IL-6 antibody among patients at high inflammatory risk.

Alpha-gal syndrome remains vastly underdiagnosed, with expanding tick geography and delayed reactions complicating recognition across specialties.

Gastroenterology in August 2026: RAS inhibitor approval for pancreatic cancer, ABTECT UC data, CRC screening mortality, and GI cancer risk.